An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)

This study has been completed.
Information provided by (Responsible Party):
AVEO Pharmaceuticals, Inc. Identifier:
First received: January 21, 2009
Last updated: June 27, 2012
Last verified: June 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2011
  Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)